[go: up one dir, main page]

MX2009011112A - Derivados de 2-heteroaril-pirrolo[3,4-cipirrolo y su uso como inhibidores de scd. - Google Patents

Derivados de 2-heteroaril-pirrolo[3,4-cipirrolo y su uso como inhibidores de scd.

Info

Publication number
MX2009011112A
MX2009011112A MX2009011112A MX2009011112A MX2009011112A MX 2009011112 A MX2009011112 A MX 2009011112A MX 2009011112 A MX2009011112 A MX 2009011112A MX 2009011112 A MX2009011112 A MX 2009011112A MX 2009011112 A MX2009011112 A MX 2009011112A
Authority
MX
Mexico
Prior art keywords
pyrrolo
heteroaryl
pyrrole derivatives
scd inhibitors
compounds
Prior art date
Application number
MX2009011112A
Other languages
English (en)
Inventor
Andreas Herling
Gerhard Zoller
Hans Matter
Stefanie Keil
Marc Dietrich Voss
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009011112A publication Critical patent/MX2009011112A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de fórmula I (ver fórmula I) en la que los radicales R1, M, A, B, D, L y R son cada uno como se definió anteriormente, y a las sales fisiológicamente compatibles. Los compuestos resultan adecuados, por ejemplo, para el tratamiento del síndrome metabólico, la resistencia a la insulina, la obesidad y la diabetes.
MX2009011112A 2007-04-27 2008-04-16 Derivados de 2-heteroaril-pirrolo[3,4-cipirrolo y su uso como inhibidores de scd. MX2009011112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07008646 2007-04-27
PCT/EP2008/003019 WO2008135141A1 (de) 2007-04-27 2008-04-16 2 -heteroaryl- pyrrolo [3, 4-c] pyrrol- derivate und deren verwendung als scd inhibitoren

Publications (1)

Publication Number Publication Date
MX2009011112A true MX2009011112A (es) 2009-10-28

Family

ID=38473076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011112A MX2009011112A (es) 2007-04-27 2008-04-16 Derivados de 2-heteroaril-pirrolo[3,4-cipirrolo y su uso como inhibidores de scd.

Country Status (17)

Country Link
US (2) US8003677B2 (es)
EP (1) EP2152711B1 (es)
JP (1) JP2010524987A (es)
KR (1) KR20100015975A (es)
CN (1) CN101663306A (es)
AR (1) AR066290A1 (es)
AT (1) ATE489389T1 (es)
AU (1) AU2008248996A1 (es)
BR (1) BRPI0810858A2 (es)
CA (1) CA2685543A1 (es)
CL (1) CL2008001215A1 (es)
DE (1) DE502008001903D1 (es)
IL (1) IL201764A0 (es)
MX (1) MX2009011112A (es)
TW (1) TW200911809A (es)
UY (1) UY31053A1 (es)
WO (1) WO2008135141A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028761A1 (de) * 2008-09-09 2010-03-18 Sanofi-Aventis 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren
WO2010108268A1 (en) * 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
BR112012016733A2 (pt) 2010-01-07 2015-09-01 Du Pont "composto, composição fungicida e método"
CN102260265B (zh) * 2010-05-24 2015-09-02 上海阳帆医药科技有限公司 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JP6254087B2 (ja) 2011-10-15 2017-12-27 ジェネンテック， インコーポレイテッド 癌を治療するためのｓｃｄ１アンタゴニスト
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
CA2878442A1 (en) 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
PE20160845A1 (es) 2013-11-26 2016-09-10 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo
HUE046820T2 (hu) 2014-03-26 2020-03-30 Hoffmann La Roche Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
WO2016046837A1 (en) 2014-09-22 2016-03-31 Cadila Healthcare Limited An improved process for preparation of pyrrolo[3,4- c] pyrrole compounds and intermediates thereof
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX377277B (es) 2015-09-04 2025-03-07 Hoffmann La Roche Derivados de fenoximetilo.
MA42923A (fr) * 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
BR112018006034A2 (pt) * 2015-09-24 2018-10-09 Hoffmann La Roche compostos bicíclicos como inibidores de atx
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
RU2725138C2 (ru) 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
CN108299437B (zh) * 2017-01-13 2022-07-08 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
JP2025536754A (ja) 2022-11-21 2025-11-07 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピロロ［３，４－ｃ］ピロールの合成

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1830837B1 (en) * 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1804799B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors

Also Published As

Publication number Publication date
KR20100015975A (ko) 2010-02-12
DE502008001903D1 (de) 2011-01-05
EP2152711A1 (de) 2010-02-17
IL201764A0 (en) 2010-06-16
US20110245263A1 (en) 2011-10-06
TW200911809A (en) 2009-03-16
US20100144594A1 (en) 2010-06-10
UY31053A1 (es) 2008-11-28
AU2008248996A1 (en) 2008-11-13
CA2685543A1 (en) 2008-11-13
BRPI0810858A2 (pt) 2014-10-29
AR066290A1 (es) 2009-08-12
CL2008001215A1 (es) 2008-09-22
EP2152711B1 (de) 2010-11-24
JP2010524987A (ja) 2010-07-22
CN101663306A (zh) 2010-03-03
WO2008135141A1 (de) 2008-11-13
ATE489389T1 (de) 2010-12-15
US8003677B2 (en) 2011-08-23

Similar Documents

Publication Publication Date Title
MX2009011112A (es) Derivados de 2-heteroaril-pirrolo[3,4-cipirrolo y su uso como inhibidores de scd.
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MY148128A (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2009003998A3 (en) Antiproliferative compounds based on 5-membered heterocycles
PL2021337T3 (pl) Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
MY148079A (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SI2114933T1 (sl) Piperidinski gpcr-agonisti
UA102514C2 (ru) Производные иминопиридина, промежуточное соединение, способ борьбы с заражением полезных растений грибами или его предупреждение и композиция на основе производной иминопиридина
TW200616623A (en) Organic compounds
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
UA107649C2 (uk) Ізоксазол-ліганди метаботропного рецептора глутамату та їх застосування як потенціаторів
GB0812642D0 (en) Compounds
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
WO2010003624A3 (en) Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
MY153921A (en) Aminopyrazole derivatives
TN2012000248A1 (en) Novel spiropiperidine compounds
MX2012002477A (es) Derivados de oxindol alqueno y sus usos para tratar obesidad, diabetes e hiperlipidemia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal